The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free ...

Komal Jhaveri, MD, FACP, breast oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center, ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

A treatment for a rare type of cancer has been accepted for use on the NHS in Scotland. The Scottish Medicines Consortium ...

Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally ...